September 23, 2017 11:33 AM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and sells generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through pharmacies, pharmacy chains, and wholesalers, as well as government or private institutions. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Gävlegatan 22

Stockholm,  113 30

Sweden

Founded in 2005

108 Employees

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Chief Executive Officer
Age: 52
Founder and Director
Age: 43
Chief Financial Officer
Age: 46
Head of development and Quality Assurance
Chief Business Development Officer
Age: 41
Compensation as of Fiscal Year 2017.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals AB Announces Group and Parent Earnings Results for the Year Ended 2016

Bluefish Pharmaceuticals AB announced group and parent earnings results for the year 2016. For the full year, the company reported group net sales were SEK 311,627,000 against SEK 283,229,000 a year ago. Operating profit was SEK 3,857,000 against operating loss of SEK 15,277,000 a year ago. Loss before tax was SEK 1,301,000 against SEK 19,857,000 a year ago. Net loss for the year, attributable to shareholders of the parent company was SEK 3,628,000 against SEK 22,175,000 a year ago. Diluted loss per share was SEK 0.04 against SEK 0.27 a year ago. Net cash used in operating activities was SEK 33,087,000 against net cash flow from operating activities of SEK 48,514,000 a year ago. Acquisition of intangible assets was SEK 19,945,000 against SEK 17,830,000 a year ago. Acquisition of property, plant and equipment was SEK 1,881,000 against SEK 4,787,000 a year ago. For the full year, the company reported parent net sales were SEK 283,438,000 against SEK 274,3829,000 a year ago. Operating profit was SEK 2,371,000 against operating loss of SEK ­12,195,000 a year ago. Loss before tax was SEK 4,464,000 against SEK 25,845,000 a year ago. Net loss for the year was SEK 4,464,000 against SEK 25,845,000 a year ago. Diluted loss per share was SEK 0.04 against SEK 0.27 a year ago. Cash flow from operating activities ­was SEK 23,965,000 against SEK 46,133,000 a year ago. Acquisition of intangible assets was SEK ­19,519,000 against SEK ­28,717,000 a year ago. Acquisition of property, plant and equipment SEK ­1,725,000 against SEK ­144 a year ago.

Bluefish Pharmaceuticals AB Announces Executive Changes

Bluefish Pharmaceuticals AB announced that the company has chosen Berit Lindholm to serve as the next Chief Executive Officer. Berit joined Bluefish in 2015 in a position as COO and is a natural choice to take over when Karl Karlsson has now decided to pursue new opportunities outside Bluefish. Berit has extensive experience within the Pharmaceutical Industry before joining Bluefish Pharmaceuticals. Karl will continue to support Bluefish long term strategy as an active board member.

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017

Bluefish Pharmaceuticals AB reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2016. For the second half, on consolidated basis, the company reported net sales of SEK 162,126000 compared to SEK 146,567,000 a year ago. Operating profit was SEK 8,574,000 compared to loss of SEK 5,284,000 a year ago. Profit after financial items was SEK 5,394,000 compared to loss of SEK 8,147,000 a year ago. Profit for the period was SEK 4,204,000 or SEK 0.05 per share before and after dilution compared loss of SEK 9,584,000 or SEK 0.12 per share before and after dilution a year ago. EBITDA was SEK 21,943,000 compared to SEK 10,052,000 a year ago. Cash used in operating activities was SEK 10,494,000 compared to cash flow from operating activities of SEK 45,403,000 a year ago. For the year, on consolidated basis, the company reported net sales of SEK 311,627,000 compared to SEK 283,229,000 a year ago. Operating profit was SEK 3,857,000 compared to loss of SEK 15,277,000 a year ago. Loss after financial items was SEK 1,301,000 compared to SEK 19,857,000 a year ago. Loss for the period was SEK 3,628,000 or SEK 0.04 per share before and after dilution compared to SEK 22,175,000 or SEK 0.27 per share before and after dilution last year. Cash used in operating activities was SEK 33,087,000 compared to cash flow from operating activities of SEK 48,514,000 a year ago. EBITDA was SEK 29.1 million compared to SEK 12.8 million a year ago. For the second half, on parent basis, the company reported net sales of SEK 145,454,000 compared to SEK 142,351,000 a year ago. Operating profit was SEK 8,480,000 compared to loss of SEK 3,475,000 a year ago. Profit for the period was SEK 4,833,000 compared to loss of SEK 13,877,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 283,438,000 compared to SEK 274,382,000 a year ago. Operating profit was SEK 2,371,000 compared to loss of SEK 12,195,000 a year ago. Loss for the period was SEK 4,464,000 compared to SEK 25,845,000 last year. The company expects higher sales growth and improved profitability for the year 2017.

Similar Private Companies By Industry

Company Name Region
Abunon AB Europe
Aditech Pharma AB Europe
Antarctic Pharma Europe
Apotek Produktion & Laboratorier AB Europe
Appetite Control Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.